Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc., a leader in the field of immunotherapeutic cancer treatments, is slated to participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference, with President and CEO Dr. Matt Coffey discussing viral strategies in cancer therapy. The company, known for developing the innovative immunotherapeutic agent pelareorep, will also engage in virtual one-on-one meetings with investors during the event. Pelareorep has shown promising synergies with existing oncology treatments and is progressing towards late-stage clinical trials in breast and pancreatic cancers, both of which have secured Fast Track designations from the FDA.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
